WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/048222    International Application No.:    PCT/US2011/055366
Publication Date: 12.04.2012 International Filing Date: 07.10.2011
A01N 43/54 (2006.01), C07D 239/42 (2006.01), C07D 471/04 (2006.01)
Applicants: ABBVIE INC. [US/US]; 1 North Waukegan Road North Chicago, IL 60064 (US) (For All Designated States Except US).
CALDERWOOD, David, J. [US/US]; (US) (For US Only).
WILSON, Noel, S. [US/US]; (US) (For US Only).
COX, Philip [US/US]; (US) (For US Only).
HOEMANN, Michael, Z. [US/US]; (US) (For US Only).
CLAPHAM, Bruce [GB/US]; (US) (For US Only).
MULLEN, Kelly, D. [US/US]; (US) (For US Only).
VASUDEVAN, Anil [IN/US]; (US) (For US Only).
VILLAMIL, Clara I [US/US]; (US) (For US Only).
LI, Bin [CN/US]; (US) (For US Only).
SOMAL, Gagandeep [KE/US]; (US) (For US Only)
Inventors: CALDERWOOD, David, J.; (US).
WILSON, Noel, S.; (US).
COX, Philip; (US).
HOEMANN, Michael, Z.; (US).
CLAPHAM, Bruce; (US).
MULLEN, Kelly, D.; (US).
VILLAMIL, Clara I; (US).
LI, Bin; (US).
SOMAL, Gagandeep; (US)
Agent: HANLEY, Elizabeth, A.; McCarter & English, LLP 265 Franklin Street Boston, Massachusetts 02110 (US)
Priority Data:
61/391,157 08.10.2010 US
61/503,368 30.06.2011 US
Abstract: front page image
(EN)The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.
(FR)La présente invention concerne de nouveaux composés de formule (I), des sels pharmaceutiquement acceptables, des métabolites biologiquement actifs, des promédicaments, des racémates, des énantiomères, des diastéréoisomères, des solvates et des hydrates de ceux-ci dans lesquels les variables sont définis comme présentement décrit. Les composés de formule (I) sont utiles en tant qu'inhibiteurs de kinase et en tant que tels seraient utiles dans le traitement de certaines affections et maladies, en particulier des affections et maladies inflammatoires et des troubles et affections prolifératifs, par exemple, des cancers.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)